Distillate Capital Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Distillate Capital Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-109,828	Closed	-$18.7M	–	135
2025 Q4	$18.7M	Sell	109,828 -1,555	-1%	-$238K	0.96%	35
2025 Q3	$14.7M	Buy	111,383 +3,572	+3%	+$428K	0.76%	66
2025 Q2	$11.4M	Sell	107,811 -16,774	-13%	-$1.82M	0.61%	98
2025 Q1	$15.5M	Buy	124,585 +1,266	+1%	+$165K	0.79%	58
2024 Q4	$15.2M	Sell	123,319 -27,830	-18%	-$3.28M	0.75%	83
2024 Q3	$16.8M	Buy	151,149 +19,733	+15%	+$2.16M	0.84%	44
2024 Q2	$14M	Buy	+131,416	New	+$14.4M	0.74%	78
2023 Q2	–	Sell	-72	Closed	-$10.5K	–	33
2023 Q1	$10.5K	Buy	+72	New	+$10.7K	2.7%	26
2021 Q4	–	Sell	-17,360	Closed	-$2.26M	–	118
2021 Q3	$2.26M	Buy	+17,360	New	+$2.62M	0.6%	99

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Distillate Capital Partners's JAZZ Position: Q1 2026 in Review

Distillate Capital Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 109,828 shares — an estimated $18.7M sold.

Distillate Capital Partners first reported a position in JAZZ in Q3 2021 and held it in 9 quarters. The position peaked at $18.7M in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Distillate Capital Partners reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Distillate Capital Partners sold 109,828 Jazz Pharmaceuticals shares in Q1 2026, an estimated $18.7M.
Distillate Capital Partners first reported a position in Jazz Pharmaceuticals in Q3 2021 and held it in 9 quarters.
Distillate Capital Partners's Jazz Pharmaceuticals position peaked at $18.7M in Q4 2025.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Distillate Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.